Harmony Biosciences Holdings (HRMY)vsModerna Inc (MRNA)
HRMY
Harmony Biosciences Holdings
$41.52
+1.02%
HEALTHCARE · Cap: $2.42B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 132% more annual revenue ($2.23B vs $959.90M). HRMY leads profitability with a 18.9% profit margin vs -141.4%. HRMY earns a higher WallStSmart Score of 75/100 (B).
HRMY
Strong Buy75
out of 100
Grade: B
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRMY.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 34.2%
Revenue surging 30.3% year-over-year
Earnings expanding 88.2% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HRMY
The strongest argument for HRMY centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.9% and operating margin at 34.2%. Revenue growth of 30.3% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : HRMY
The primary concerns for HRMY are Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
HRMY profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
HRMY is growing revenue faster at 30.3% — sustainability is the question.
HRMY generates stronger free cash flow (92M), providing more financial flexibility.
Bottom Line
HRMY scores higher overall (75/100 vs 21/100), backed by strong 18.9% margins and 30.3% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harmony Biosciences Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?